Prescription drug data

Each calendar year, the board shall identify nine drugs and at least one insulin product under ORS 646A.694 that the board determines may create affordability challenges for the health care systems or high out-of-pocket costs for patients in this state. The Oregon Prescription Drug Price Transparency program provides the board with the list of prescription drugs for review submitted under ORS 646A.689 (2) and (6), and ORS 743.025. This page contains aggregated data files for the board's affordability review as outlined in OAR 925.200.0010 and OAR 925.200.0020. The board strictly maintains the confidentiality of any information collected, used or relied upon for the review that is protected trade secret, confidential, or proprietary information, as defined in ORS 192.345.

Jan. 26, 2024 affordability review reports

• Tresiba & Tresiba FlexTouch Affordability Review - version 2
  
• Humulin R U-500 KwikPen Affordability Review - version 2
  

Jan. 10, 2024 affordability review reports

• Tresiba & Tresiba FlexTouch Affordability Review - version 1
• Humulin R U-500 KwikPen Affordability Review - version 1

Prescription drug and insulin list for affordability review (approved by the board on Dec. 13, 2023)

• Oregon PDAB prescription drug and insulin list for affordability review (PDF)

Dec. 13, 2023 board revised subset lists

• Prescription drugs
  
• Insulin
  
• Data calculations and methodology (PDF)

• Revised prescription drug subset list (Excel)
  
• Insulin data analysis 2021 through 2022 (Excel)